BofA moved to No Rating on Organon (OGN) after the company announced that it has agreed to be acquired by Sun Pharma for $14 per share in cash. The Sun deal is expected to close in early 2027 and the firm believes shares no longer trades on fundamentals, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: